Industry Overview

Canada silent attack market was valued $139.3 million in 2025 and is projected to reach $330.4 million by 2035, growing at a CAGR of 9.0% from 2026 to 2035. Silent myocardial infarction is a critical subset of cardiovascular disease in which symptoms are minimal or absent, often resulting in delayed diagnosis and increased risk of severe complications. The market encompasses a wide range of products, including electrocardiogram (ECG) systems, cardiac biomarker tests such as troponin, advanced imaging technologies, wearable monitoring devices, as well as interventional procedures and pharmacological treatments. Growth is primarily driven by the rising burden of cardiovascular diseases, an aging population, and the increasing prevalence of risk factors such as diabetes and hypertension in Canada. Additionally, the healthcare system’s growing emphasis on early detection and preventive cardiology is accelerating the adoption of advanced diagnostic solutions across hospitals, cardiology clinics, and diagnostic centers.

Recent technological advancements are further strengthening market growth by enabling earlier and more accurate detection of silent cardiac events. In March 2026, iRhythm Technologies presented clinical data at ACC 2026 demonstrating that its Zio ambulatory ECG monitoring system effectively identifies clinically significant arrhythmias, particularly among high-risk patient populations. The findings highlighted a substantial prevalence of undiagnosed arrhythmias in individuals with cardiometabolic conditions, reinforcing the importance of continuous monitoring for early intervention. Similarly, in August 2025, GE HealthCare introduced the Vivid Pioneer, an AI-powered cardiovascular ultrasound system designed to enhance imaging speed and diagnostic precision. By integrating advanced 2D, 4D, and AI-driven capabilities, the system improves cardiac assessment and workflow efficiency, supporting early detection of asymptomatic conditions such as silent heart attacks and enhancing diagnostic capabilities across healthcare facilities.

Market Dynamics

Smart Wearables Revolutionizing Early Cardiac Detection

Wearable and remote cardiac monitoring devices are rapidly transforming preventive healthcare, driven by the growing adoption of home-based care solutions. These technologies enable continuous and real-time tracking of heart activity, allowing earlier identification of potential cardiac abnormalities. In January 2026, AliveCor received FDA clearance for new cardiac determinations in its Kardia 12L ECG system, enhancing its ability to detect multiple heart conditions, including myocardial infarction. The AI-powered handheld ECG device simplifies cardiac screening and expands access to high-quality diagnostics across both clinical and remote settings. Its portability and ease of use make it particularly valuable for high-risk and underserved populations. This advancement significantly improves the likelihood of early and incidental detection of silent heart attacks. As a result, wearable monitoring solutions are strengthening diagnostic pathways and supporting more proactive cardiovascular care across hospitals and home care environments.

Next-Gen Imaging Elevates Precision in Interventional Cardiology

Interventional procedures, including angioplasty and stent placement, play a vital role in managing patients diagnosed with silent heart attacks. These minimally invasive techniques are widely used to restore blood flow and prevent further cardiac complications. In October 2025, Terumo received FDA 510(k) clearance for its OPUSWAVE dual sensor imaging system. The technology integrates optical frequency domain imaging (OFDI) and intravascular ultrasound (IVUS) into a single catheter platform. This combination enables simultaneous, high-resolution visualization of coronary arteries during procedures. As a result, clinicians can assess plaque characteristics and vessel conditions more accurately. The innovation enhances procedural precision and supports better clinical decision-making. It also strengthens the role of advanced imaging in early detection and evaluation of silent cardiac events within interventional cardiology.

Market Segmentation

• Based on the diagnosis, the market is segmented into electrocardiogram (ECG), cardiac biomarker testing (troponin, CK-MB), cardiac imaging, and wearable & remote monitoring devices.
• Based on treatment type, the market is segmented into pharmacological treatment, interventional procedures, and lifestyle & preventive management.
• Based on end-user, the market is segmented into hospitals, cardiology clinics, diagnostic centers, and home care settings.

Advanced Diagnostics Accelerating Early Detection of Silent Heart Attacks

Diagnostic technologies continue to lead the market due to strong reliance on ECG, cardiac biomarkers, and imaging systems for identifying silent myocardial infarction. These tools play a crucial role in detecting asymptomatic cardiac events that would otherwise remain unnoticed. Among them, high-sensitivity troponin assays are particularly important, as they enable early and accurate identification of myocardial injury. In March 2026, Roche Diagnostics received FDA 510(k) clearance for its cobas c 703 and cobas ISE neo analytical units, designed to enhance high-throughput clinical chemistry testing. The systems can process up to 2,000 tests per hour, significantly improving laboratory efficiency and turnaround time. This advancement supports large-scale biomarker testing, including cardiac markers, across hospitals and diagnostic centers. As a result, healthcare providers can achieve faster diagnosis and timely intervention. Overall, such innovations are strengthening diagnostic capabilities and reinforcing the dominance of this segment in the market.

Market Players Outlook

The major companies operating in the Canada silent heart attack market include Cardinal Health, Pfizer, AstraZeneca, Abbott, and Medtronic, among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Development

• In 2026, University Health Network collaborated with Apple Inc. to demonstrate through clinical research that smartwatch-based monitoring can track physiological signals like heart rate and oxygen levels to identify early, asymptomatic cardiac deterioration, supporting detection of silent heart attacks through continuous remote monitoring.
• In 2025, Vancouver Coastal Health Research Institute collaborated with University of British Columbia to develop wearable technologies such as smartwatches and rings with integrated sensors capable of detecting cardiac events and automatically alerting emergency responders, addressing the challenge of unwitnessed and silent cardiac episodes

The Report Covers

• Market value data analysis of 2025 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Key companies operating in the Canada silent heart attack market
• Based on the availability of data, information related to new protections and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.